source
- US biotech faces growth slowdown as China’s coordinated investment threatens industryDuring a BioSpace webinar, industry experts warned that uncertainty in U.S. policy is slowing biotech growth while China accelerates its life-science sector with deliberate investment. Strand Ther…
- Neurosterix raises $105 million Series B to advance schizophrenia candidateNeurosterix announced it has closed a $105 million Series B financing round. The capital will be used to develop its lead drug candidate for schizophrenia, which targets a pathway also addressed by…